American Journal of Microbiological Research
ISSN (Print): 2328-4129 ISSN (Online): 2328-4137 Website: http://www.sciepub.com/journal/ajmr Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
American Journal of Microbiological Research. 2017, 5(2), 32-36
DOI: 10.12691/ajmr-5-2-2
Open AccessArticle

Prevalence of Multidrug-Resistant Tuberculosis among Smear Positive Pulmonary Tuberculosis Patients in Eastern Sudan

Muataz M. Eldirdery1, , Intisar E. Alrayah2, Mona OA. Awad ElkareIm3, , Fatima A. Khalid4, Asrar M A/Salam Elegail5, Nuha Y. Ibrahim5, Eman OM. Nour5, Rahma H. Ali5, HAMDAN M. HAMDAN6, Nagi M. Awad7, Yassir M. Mohamed Ahmed1, Nihad M A. Elhaj1 and Atif A. Elagib8

1Department of Microbiology, Tropical Medicine Research Institute National Center for Research, Khartoum, Sudan

2Department of Microbiology, Tropical Medicine Research Institute National Center for Research, Khartoum, Sudan and Faculty of Applied Medical Science, Shaqra University, Shaqra, Saudi Arabia

3Blood Transfusion Service, National Blood Transfusion Center, Ministry of Health, Khartoum, Sudan

4Tuberculosis Research Center, University of Kassala, Kassala, Sudan

5National Tuberculosis Reference Laboratory, National Laboratory of Public Health, Khartoum Sudan

6Consultant of Tuberculosis control program, Khartoum, Sudan

7Tuberculosis control program, Khartoum, Sudan

8Tropical Medicine Research Institute National Center for Research, Deputy Director of National Center for Research, Khartoum, Sudan

Pub. Date: April 12, 2017

Cite this paper:
Muataz M. Eldirdery, Intisar E. Alrayah, Mona OA. Awad ElkareIm, Fatima A. Khalid, Asrar M A/Salam Elegail, Nuha Y. Ibrahim, Eman OM. Nour, Rahma H. Ali, HAMDAN M. HAMDAN, Nagi M. Awad, Yassir M. Mohamed Ahmed, Nihad M A. Elhaj and Atif A. Elagib. Prevalence of Multidrug-Resistant Tuberculosis among Smear Positive Pulmonary Tuberculosis Patients in Eastern Sudan. American Journal of Microbiological Research. 2017; 5(2):32-36. doi: 10.12691/ajmr-5-2-2

Abstract

Background: The prevalence of multidrug-resistant tuberculosis (MDR-TB) is increasing throughout the world. Although previous treatment for TB is the most important risk factor for development of MDR-TB, treatment-naïve patients are also at risk due to either spontaneous mutations or transmission of drug-resistant strains. The main objective of this study to determine the prevalence of MDR-TB among new and retreatment cases of sputum-positive pulmonary TB in Eastern Sudan. Methods: A cross sectional study involving retreatment and newly diagnosed cases of sputum-positive pulmonary tuberculosis between November 2011 to October 2012 was carried out in Eastern Sudan. All sputum specimens were positive smear TB were subjected to Line Probe assay, culture and drug susceptibility test (DST) for first-line drug. MDR-TB was defined as TB caused by bacilli showing resistance to at least isoniazid and rifampicin. Results: A total of 109 cases of sputum-positive pulmonary tuberculosis were enrolled. Out of 109 patients screened (88 new case patients and 21 previously treated case patients); MDR TB prevalence was 4(36.36%) and 7 (63.64%) among new case-patients and previously treated case patients, respectively. The age group 31-45 years was recorded the highest frequency of MDR-TB infection 5 (45.45%). Females were more affected than Males 7 (63.6%) and 4 (36.4%) respectively. Among the MDR cases only one patient was HIV positive and it was new case. Discussion and conclusion: This study showed that the prevalence of MDR tuberculosis among the new and retreatment cases in Kassala State is much higher than what was reported previously. This is the first study in Geddarif state and there were no previous studies documented or were published, other studies is needed to know the really reasons of the continuously increasing of MDR TB in Geddarif and Kassala states.

Keywords:
tuberculosis MDR Eastern Sudan

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Vasantha M, Gopi PG, Subramani R; Survival of tuberculosis patients treated under dots in a rural tuberculosis unit (TU), South India.Indian J Tuberc., 2008; 55(2): 64-69.
 
[2]  World Health Organization (WHO), Global Tuberculosis Report 2014, Geneva, Switzerland.
 
[3]  CDC. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs – worldwide, 2000-2004.Morb Mortal Wkly Report (2006). 55:301-305.
 
[4]  L.P. Ormerod, Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment, Br. Med. Bull. 73-74 (2005) 17-24.
 
[5]  Sharma SK, Mohan A; Multidrug resistant tuberculosis. Indian J Med Res., 2004; 120(4): 354-376.
 
[6]  Lango DL, Fauci AS, Kaser D, Hauser S L, Janeson J L, Loscalzo J; Harrison’s Principles of Internal Medicine. 18thedition. NewYork, McGraw Hill, 2012: 1340-1377.
 
[7]  World Health Organization Global Tuberculosis report 2015.
 
[8]  World Health Organization WHO, Laboratory Services in Tuberculosis Control Culture (1998). Part III PP (57-75).
 
[9]  Koneman EW; Mycobacteria. In Koneman’s Color Atlas and Textbook of Diagnostic Microbiology. 6th edition, Philadelphia, Lippincott Williams and Wilkins, 2006:1065-1117.
 
[10]  National TB Control Programme. Manual of Standard Operating Procedures (SOPs). Culture of Mycobacterium tuberculosis and Drug Susceptibility Testing on solid Medium Intermediate Reference Laboratory for Tuberculosis - Central TB Division, (Ministry of Health & Family Welfare) (2009). New Delhi-Version No. 01.01 Date: 01/04.
 
[11]  Sethi S, Sharma S, Sharma SK, Meharwal SK, Jindal SK and Meera S. Drug susceptibility of Mycobacterium tuberculosis to primary anti- tubercular drugs by nitrate reductase assay (2004). Indian J Med Res. 120, PP 468-471.
 
[12]  World Health Organisation: Policy Statement. Molecular Line Probe Assaysfor Rapid Screening of patients at risk of mul tidrug resistant tuberculosis (MDR-TB), 2008. http://www.who.int/tb/dots/laboratory/lpa_policy.pdf.
 
[13]  Hain Lifescience. Genotype® MTBDRplus product insert. Version http://www.hainlifescience.de/en/products/microbiology/mycobacteria/genotypemtbdrplus.html
 
[14]  Martin G and Lazarus A. Epidemiology and Diagnosis of Tuberculosis. Recognition of At-risk Patients is Key to Detection (2000). Postgrad. Med. 108:42-44, 47-50, 53-54.
 
[15]  Federal Ministry of Health of Ethiopia. Guideline for program and clinical management of drug resistant tuberculosis 2009. Addis Ababa, Ethiopia: FMOH;.
 
[16]  World Health Organization. WHO report. Global Tuberculosis control 2013. Geneva: Switzerland.
 
[17]  World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB) - 2010 global report on surveillance and Response. Geneva: Switzerland.
 
[18]  World Health Organization. WHO report 2011. Global Tuberculosis Control. Geneva: Switzerland.
 
[19]  Khalid F.A. and Mukhtar M. M. Epidemiology of Tuberculosis and molecular characterization of drugs resistance isolates of mycobacterium tuberculosis from kassla state, Institute of Endemic Diseases-University of Khartoum (2009). Thesis.
 
[20]  Fatima A. Khalid, Zuhal A. Hamid b, M.M. Mukhtar. Tuberculosis drug resistance isolates from pulmonary tuberculosis patients, Kassala State, Sudan (2015). International Journal of Mycobacteriology. 4. 44-47.
 
[21]  Mohammed E. M., Saeed N. S. Isolation, Identification and Antimicrobial Sensitivity of Mycobacterium tuberculosis from Patients with Pulmonary Infection M.V.C. University of Khartoum (2008). Thesis.
 
[22]  Jain A, Mondal R, Prasad R, Singh K, Ahuja RC. Prevalence of multidrug resistant Mycobacterium tuberculosis in Lucknow, Uttar Pradesh. Indian J Med Res 2008; 128: 300-6.
 
[23]  D’souza DT, Mistry NF, Vira TS, Dholakia Y, Hoffner S, Pasvol G, et al. High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Public Health 2009; 211: 1-9.
 
[24]  World Health Organization WHO Anti-Tuberculosis Drug Resistance in the World. Report No.4. Geneva, Switzerland. The WHO / IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance2008; p. 394. WHO/HTM/TB.
 
[25]  Paramasivan CN, Venkataraman P. Drug resistance in tuberculosis in India. Indian J Med Res. 2004; 120:377-86. [PubMed]
 
[26]  Snider DE, Jr, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug resistant and drug susceptible bacilli. Am Rev Respir Dis. 1985; 132:125-32. [PubMed].